Ceribell
Lets frontline nurses screen ICU patients for seizures with a six-minute bedside EEG headband.
Something off on this page? Send us feedback.
Profile
Makes a portable EEG headband and recorder that a nurse can apply to an ICU patient within six minutes, paired with an AI layer that flags seizures automatically and alerts the care team around the clock. Revenue comes from selling single-use headbands alongside a recurring software subscription for the detection and monitoring layer.
Makes a bedside headband-and-recorder system that screens ICU and emergency patients for seizures, built so a floor nurse rather than a specialist can apply it and get a reading within six minutes. An AI layer on top of the hardware flags abnormal activity and alerts the care team continuously, extending coverage beyond the hours a dedicated EEG reader is available.
Revenue splits between single-use headbands sold per patient and a recurring software subscription covering the detection algorithm, recorder, and clinician portal. Clearances have widened from adult seizure detection to pediatric and neonatal patients, and the same platform now covers delirium monitoring, with stroke detection under regulatory review.
Adoption runs hospital by hospital against an installed base of conventional EEG systems from established neurodiagnostics vendors, and further indication clearances remain central to expanding use beyond acute seizure care.
Company facts
Key statistics
Year to date +11.2% · Average volume (30d) 407.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 18, 2026 | Barclays | Upgrade | Neutral | ||
| Aug 11, 2026 | Canaccord Genuity | Reiterate | Buy | $25 | $26 |
| May 12, 2026 | Canaccord Genuity | Reiterate | Buy | $30 | $25 |
| Dec 15, 2025 | BTIG | Reiterate | Buy | $30 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026Q2 FY26 | −$0.47 | −$0.51 | −8.2% | $27.3M | $28.1M | +3.0% | +10.41% |
| May 11, 2026Q1 FY26 | −$0.39 | −$0.52 | −33.3% | $26.1M | $26.5M | +1.6% | −16.50% |
| Feb 24, 2026Q4 FY25 | −$0.43 | −$0.36 | +16.3% | $23.9M | $24.8M | +3.6% | −4.77% |
| Nov 4, 2025Q3 FY25 | −$0.43 | −$0.37 | +14.0% | $23.9M | $22.6M | −5.7% | +7.88% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $20.5M | $21.2M | $22.6M | $24.8M | $26.5M | $28.1M | |
| Gross profit | $18.0M | $18.7M | $19.9M | $21.6M | $23.1M | $25.9M | |
| Operating income | −$14.2M | −$15.0M | −$14.6M | −$14.6M | −$20.7M | −$20.0M | |
| Net income | −$12.8M | −$13.6M | −$13.5M | −$13.5M | −$19.7M | −$19.3M | |
| Diluted EPS | −$0.36 | −$0.38 | −$0.37 | −$0.36 | −$0.52 | −$0.51 | |
| Gross margin | 87.9% | 88.1% | 88.3% | 87.3% | 87.3% | 92.3% | |
| Operating margin | -69.3% | -70.5% | -64.8% | -58.9% | -78.3% | -71.1% |
Fiscal years (4-quarter sums)FY23 $45.2M · FY24 $65.4M · FY25 $89.1M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $129.3M · Total debt $21.9M · Total assets $166.3M · Shareholders' equity $128.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 37.94M · Float 24.72M · 65.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 5.69M | 15.00% | 13F | Aug 13, 2026 |
| TPG GP A, LLC · other: Former 10% Owner | 3.77M | 9.92% | Form 4 | Jun 30, 2026 |
| Longitude Venture Partners IV, L.P. | 2.48M | 7.00% | 13D | Oct 22, 2024 |
| Bakker Juliet Tammenoms · director | 2.26M | 5.96% | Form 4 | Jun 4, 2026 |
| Red Tree Management, LLC | 2.21M | 5.81% | 13F | Jul 22, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 21, 2026 | Joseph S. Manni | officer: Chief Revenue Officer | −1,361 | $24.02 |
| Aug 21, 2026 | Scott Blumberg | officer: Chief Financial Officer | −1,521 | $24.02 |
| Aug 21, 2026 | Raymond Woo | officer: Chief Technology Officer | −1,979 | $24.02 |
| Aug 24, 2026 | David Foehr | officer: Senior VP, Finance and PAO | −859 | $23.95 |
| Aug 21, 2026 | David Foehr | officer: Senior VP, Finance and PAO | −993 | $24.02 |
Peers
- GE HealthCare
Bundles EEG and BIS as add-on modules inside multi-parameter ICU monitors
- Philips (ADR)
Multi-parameter monitor EEG module for IntelliVue bedside platforms
- Compass Minerals
Clinical EEG amplifiers for LTM and ICU studies via Neuroscan Grael
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Ceribell | $23.73 | +0.17% | $900.4M | — | — | 8.8 | +32.5% |
| GE HealthCare | $71.73 | −0.01% | $32.40B | 20.8 | 13.8 | 1.6 | +5.8% |
| Philips (ADR) | $26.72 | +0.06% | $26.12B | 19.9 | 13.7 | 1.3 | −2.9% |
| Compass Minerals | $24.62 | −0.06% | $1.03B | 57.3 | 21.1 | 0.8 | +0.3% |
| Median | 20.8 | 13.8 | 1.3 | +0.3% |